OneClick Social Engagement Intervention for Well Aging

Phase-Based Progress Estimates
CJE Senior Living, Chicago, IL
Well Aging+3 More
OneClick Social Engagement Intervention - Other
All Sexes
What conditions do you have?

Study Summary

The goal of this randomized controlled trial is to rigorously assess the efficacy of an 8-week social engagement OneClick intervention. A total of 120 older adults with and without mild cognitive impairment (60 per group) will be randomized after a baseline assessment to the social engagement OneClick intervention group or the waitlist control group. Participants assigned to the intervention group will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants assigned to the waitlist control group will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Subsequently, as an extension to this study, participants assigned to the waitlist control group will have an opportunity to participate in 8 weeks of social engagement OneClick intervention, with intervention effects assessed at week 4 and week 8.

Eligible Conditions

  • Well Aging
  • Aging
  • Mild Cognitive Impairment (MCI)

Treatment Effectiveness

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: Baseline, Week 4, Week 8, Waitlist Group Extension Week 4, Waitlist Group Extension Week 8

Week 8
Change in Loneliness Measured by University of California - Los Angeles (UCLA) Loneliness Scale
Change in Social Isolation Measured by Friendship Scale
Change in Social Network Measured by Lubben Social Network Index
Week 8
Change in Social Activity Measured by Social Activity Frequency
Week 8
Change in Quality of Life Measured by Quality of Life in Alzheimer's Disease
Week 8
Change in Computer Proficiency Measure by Computer Proficiency Questionnaire (Short -Form)
Change in System Usability Measured by System Usability Scale
Change in Technology Acceptance Measured by Technology Acceptance Survey

Trial Safety

Trial Design

1 Treatment Group

OneClick Social Engagement Intervention Group
1 of 1
Experimental Treatment

120 Total Participants · 1 Treatment Group

Primary Treatment: OneClick Social Engagement Intervention · No Placebo Group · N/A

OneClick Social Engagement Intervention Group
Experimental Group · 1 Intervention: OneClick Social Engagement Intervention · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, week 4, week 8, waitlist group extension week 4, waitlist group extension week 8
Closest Location: CJE Senior Living · Chicago, IL
Photo of Chicago 1Photo of Chicago 2Photo of Chicago 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Well Aging
0 CompletedClinical Trials

Who is running the clinical trial?

University of Illinois at Urbana-ChampaignLead Sponsor
162 Previous Clinical Trials
31,854 Total Patients Enrolled
Wendy A Rogers, Ph.D.Principal InvestigatorUniversity of Illinois at Urbana-Champaign

Eligibility Criteria

Age 65+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are fluent in English.
Passing score on Telephone Interview for Cognitive Status - Modified (TICS-M) of 22 and above included.
You have a score of less than 9 on the Geriatric Depression Scale.
You are willing to comply with all study procedures and are available for the duration of the study.
You have access to and the ability to use the necessary resources for participating in technology-based intervention.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.